e-Drug3D

1616

APROCITENTAN

INN
APROCITENTAN

cas 1103522-45-7

CLASS

CARDIOVASCULAR
ANTIHYPERTENSIVE
PULMONARY ARTERIAL HYPERTENSION (PAH)
ENDOTHELIN RECEPTOR ANTAGONIST ET-1
PREVENTS THE BINDING OF ET-1 TO ITS RECEPTORS ETA AND ETB
METABOLITE 20 PERCENT AS POTENT AS THE PARENT DRUG IN VITRO

ROUTE (list)

ORAL

ATC code

C02KN01

PK parameters

Tmax 4.5 HOUR
VD 20 LITER
Cl 0.3 LITER / HOUR
PPB 99 PERCENT
t1/2 41 HOUR

Solubility

INSOLUBLE IN WATER

Target

TARGET ENDOTHELIN RECEPTOR ET-1

DrugCentral

Download SDF file

Sulfamide, N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-

Formula:
C16H14Br2N6O4S

Calculated chemical properties:

MW 546.20
NB_atoms 29
XLogP 2.53
PSA 128.103
NB_HD 3
NB_HA 10
fsp3 0.12
Lipinski(0=no;1=yes) 0

FDA
NDA 217686 (label) INN (APROCITENTAN) TRYVIO (IDORSIA) APPROVAL= AP YEAR= 2024 NEWMOLECULARENTITY